Translational Awards support researchers developing cardiovascular medicines and technologies, funding work from initial development to phase II trials to advance patient benefit and commercialisation.
Funder: British Heart Foundation
Due Dates: February 3, 2027 (Preliminary) | August 4, 2027 (Preliminary) | Full application deadline provided upon invitation
Funding Amounts: No funding request limit; justified project costs for up to 3 years
Summary: Supports early-stage cardiovascular medicines and technologies progressing towards patient benefit, market development and commercialisation.
Key Information: The principal investigator must work at an established UK research institution, with applications developed alongside its Technology Transfer Office.
The British Heart Foundation’s Translational Awards support novel cardiovascular medicines and technologies moving from discovery science towards human studies, phase II trials, patient benefit and commercialisation. Projects may begin and end anywhere from initial development through preclinical studies to early-phase clinical trials, up to and including phase II. The endpoint must represent a significant scientific or value inflection point.
Supported approaches include novel therapeutics, repurposed drugs, devices, surgical techniques, diagnostics, imaging, digital solutions, cell therapy and regenerative medicine, and early-phase studies evaluating efficacy and safety. The scheme prioritises unmet clinical needs, supporting proof-of-concept data, a strong intellectual property position and credible, milestone-driven delivery. Proposals should offer a development proposition capable of attracting follow-on investment, with a clear route through regulatory processes towards market development.